Ensign Peak Advisors
MAZE

Ensign Peak Advisors’s Maze Therapeutics MAZE Stock Holding History

Ensign Peak Advisors’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.55M Hold
185,794
– – 0.01% 510
2025
Q4 		$7.7M Buy
185,794
+115,129
+163% +$3.96M 0.01% 454
2025
Q3 		$1.83M Buy
70,665
+52,126
+281% +$880K ﹤0.01% 824
2025
Q2 		$227K Buy
+18,539
New +$193K ﹤0.01% 1674

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors's MAZE Position: Q1 2026 in Review

Ensign Peak Advisors held its Maze Therapeutics (MAZE) position steady in Q1 2026 at 185,794 shares worth $5.55M. The position accounts for 0.01% of the portfolio, ranked #510.

Ensign Peak Advisors first reported a position in MAZE in Q2 2025 and has held it in 4 quarters since. The position peaked at $7.7M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Ensign Peak Advisors held 185,794 shares of Maze Therapeutics worth $5.55M as of Q1 2026.
  • Ensign Peak Advisors left its Maze Therapeutics share count unchanged in Q1 2026.
  • Maze Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #510 holding.
  • Ensign Peak Advisors first reported a position in Maze Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ensign Peak Advisors's Maze Therapeutics position peaked at $7.7M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.